Rchr

J-GLOBAL ID：200901047933769415 Update date: Mar. 01, 2024

OHASHI SACHIYO

オオハシサチヨ | OHASHI SACHIYO

Affiliation and department：
Job title： Assistant Professor
Papers (15)：

Toru Tanaka, Sachiyo Ohashi, Akihiko Takashima, Shunsuke Kobayashi. Dendritic distribution of CDK5 mRNA and p35 mRNA, and a glutamate-responsive increase of CDK5/p25 complex contribute to tau hyperphosphorylation. Biochim Biophys Acta. 2022. 1866. 7. 130135-130135
Toru Tanaka, Sachiyo Ohashi, Akihiko Takashima, Shunsuke Kobayashi. Glutamate-responsive translation of dendritic GSK3β mRNA triggers a cycle for amplification of reactivated preexisting GSK3β that is indispensable for tau hyperphosphorylation. Neurochem Int . 2020. 139. 104808-104808
Tanaka T, Ohashi S, Saito H, Wada T, Aoyama T, Ichimaru Y, Miyairi S, Kobayashi S. Indirubin 3'-oxime inhibits anticancer agent-induced YB-1 nuclear translocation in HepG2 human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2018. 496. 1. 7-11
Kosuge Y, Saito H, Haraguchi T, Ichimaru Y, Ohashi S, Miyagishi H, Kobayashi S, Ishige K, Miyairi S, Ito Y. Indirubin derivatives protect against endoplasmic reticulum stress-induced cytotoxicity and down-regulate CHOP levels in HT22 cells. Bioorg Med Chem Lett. 2017. 27. 23. 5122-5125
Toru Tanaka, Sachiyo Ohashi, Shunsuke Kobayashi. Four nucleocytoplasmic-shuttling proteins and p53 interact specifically with the YB-NLS and are involved in anticancer reagentinduced nuclear localization of YB-1. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2016. 478. 3. 1363-1369

ｍore...

MISC (4)：

Lectures and oral presentations (59)：

高リン酸化Tauの凝集におけるカルシウムイオンの影響
(日本薬学会第144年会 2024)
KANSL1 mRNAの新奇3’-UTRバリアントはtau mRNAに相補的な領域を持ち翻訳を活性化する
(第46回日本分子生物学会年会 2023)
樹状突起におけるTauの局所翻訳と過剰リン酸化
(日本薬学会第143年会 2023)
Tauの過剰リン酸化に関わるCDK5の樹状突起発現機構と活性化機構
(第45回日本分子生物学会年会 2022)
がんの増悪を引き起こすYB-1タンパク質の核移行を特異的に阻害するindirubin誘導体の効果と核移行阻害メカニズム
(日本薬学会第142年会 2022)

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM